Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials
- 1 March 2016
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 34 (13), 1496-1503
- https://doi.org/10.1016/j.vaccine.2016.02.023
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: A randomized, double-blind, placebo-controlled trialVaccine, 2015
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2014*Annals of Internal Medicine, 2014
- Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic TechniquesPLOS ONE, 2013
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in JapanVaccine, 2010
- Clinical and economic burden of community-acquired pneumonia among adults in EuropeThorax, 2010
- The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?Clinical Microbiology & Infection, 2009
- Efficacy of pneumococcal vaccination in adults: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategiesEpidemiology and Infection, 2000